Skip to main content
. 2016 Nov 3;6(1):159–172. doi: 10.1016/j.molmet.2016.10.009

Figure 1.

Figure 1

Endo1 downregulation in the ARC of obese mice after DIO decreases body weight but impairs glucose homeostasis. (A) Experimental Protocol for the “Obesity reversal experiment”. (B) Body weight of obese mice after stereotactic injection of lentiviral vectors expressing control (CTRL) or Endo1 shRNA in the ARC and kept on HFD (CTRL or Endo1-HFD-HFD) or switched to CD (CTRL or Endo1-HFD-CD). CTRL-HFD-CD vs Endo1-HFD-CD: *, p < 0.05; **, p < 0.01; ***, p < 0.005. CTRL-HFD-HFD vs Endo1-HFD-HFD: #, p < 0.05; ##, p < 0.01 (n = 15–20 per group). (C) Fasting blood glucose at week 32. *, p < 0.05; ***, p < 0.005 (n = 15–20 per group). (D) Intraperitoneal Glucose Tolerance Test (ip-GTT) (2 g/kg). CTRL-HFD-CD vs Endo1-HFD-CD: #, p < 0.05. CTRL-HFD-HFD vs Endo1-HFD-HFD: *, p < 0.05; **, p < 0.01; ***, p < 0.005 (n = 15–20 per group). (E) Area Under the Curve of (D). *, p < 0.05; **, p < 0.01. Data are presented as means ± SEM.